Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

eatment periods. Adverse events were generally of mild to moderate severity and occurred in all three treatment groups and the placebo group. The frequency of adverse events was dose-ordered across the 10 mg, 15 mg and 20 mg doses, with the 20 mg group reporting the highest number of events. There were few reports of gastrointestinal complaints in any of the three dose groups.

About Xerostomia

Xerostomia, or dry mouth, is the result of decreased salivary flow and is a symptom of a number of underlying conditions. Causes of dry mouth include Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. Xerostomia can also be a side effect of medications and is associated with aging.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions, including statements regarding the potential of NGX267 as a treatment for xerostomia, the potential of NGX267 to treat xerostomia associated with Sjogren's syndrome, radiation treatment to the head and neck, HIV-related salivary gland disease, aging, or side effects of medication, and the potential t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , August 1, 2014 ... Market by Type (Traditional Wound Closure, Anti infective), Basic ... (Artificial Skin & Skin Substitutes), Pressure Relief Devices, ... MarketsandMarkets, the global Wound Care Market is expected to ... in 2014, growing at a CAGR of 3.2% ...
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... AUSTIN, Texas, May 22, 2012 SmallCapVoice.com, Inc. ... Medical Marijuana, Inc. (PINKSHEETS: MJNA) is now available. ... . Recent company activity and highlights: ... approximately $1.21 million on gross revenues of $1.79 ...
... Laboratory, Inc. (HDL, Inc.), a CAP accredited leader in ... with a non-restricted educational grant to further its mission ... the United States. In addition to the grant, HDL, ... of the 2012 Annual Scientific Sessions in Scottsdale, Arizona ...
Cached Medicine Technology:Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 2Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 3Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 4Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona 2
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk ... in San Francisco, CA. Now in its fourth year, ... Union Square hotel. , “We are excited about returning ... with ACA compliance issues,” Quirk Healthcare Foundation Executive Director, ... attendees guidance with NextGen implementation and use, electronic records ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... Oxford Gene Technology (OGT) is ... products include CytoSure heamatological cancer +SNP Array, CytoSure ... UPD array, CytoSure ISCA sample tracking spike-ins and ... such as targeted sequencing services, SureSeq Solid Tumour ... expression analysis, cytosure services and aCGH for CNV ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... on the Atkins low-carbohydrate diet lose more weight than those ... pressure and cholesterol levels dropped considerably. ,On average, ... months. The average weight loss was 5.7 pounds for women ... diet and 3.5 pounds for those following the Zone weight-loss ...
... that a plane accident that left a father and young ... a suicide// crash. ,Two people were killed Monday ... the edge of a small local airport in Bedford - ... destroyed the house of the former mother-in-law of the divorced ...
... greens and beans aren't the only foods that pack ... healthy// start to pregnancy. ,Researchers now have ... a full day's worth of the nutrient in a ... week's online edition of the journal PNAS, Proceedings of ...
... the Chulalongkorn Hospital here removed a 60-cm-long sword that had ... and exited// near his left ear, news reports said Wednesday. ... a stable condition after the sword's removal from his face ... Tuesday, reported the Thai Rath newspaper. ,Ronnachai received ...
... Institute for Biological Studies, have discovered that silencing a gene ... reduce insulin resistance, in animal models, it will also help ... , The peptide in question is ucocortin 3. This ... produced in the insulin secreting cells of the pancreas and ...
... of a brain system that regulates appetite. The study also ... new drug therapies to help individuals lose weight. ... around 30 percent are obese. The study conducted by scientists ... the March issue of Cell Metabolism. ,The research ...
Cached Medicine News:Health News:Atkin’s Low-carb Diet Best for Weight Los 2Health News:Scientists Genetically Engineer Tomatoes With Enhanced Folate Content 2Health News:Scientists Explore Ways to Reduce Insulin Resistance by ‘handcuffing’ Gen 2Health News:Targeting SOCS-3 can Control Obesity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: